Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Congress 2022 | Fibrotic progression of ET and PV: clinical and biological considerations

Raajit Rampal • 24 Nov 2022
MPN Congress 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, gives a presentation on the clinical and biological considerations for fibrotic progression in essential thrombocythemia (ET) and polycythemia vera (PV) at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.

More from Raajit Rampal

Interferon in PV and ET: unanswered questions 0:45
Interferon in PV and ET: unanswered questions
Raajit Rampal • 24 Aug 2024
The evolving treatment landscape in PV 0:56
The evolving treatment landscape in PV
Raajit Rampal • 24 Aug 2024
TP53 mutation in MPNs and investigating LSD1 inhibition in TP53-mutant murine models 1:27
TP53 mutation in MPNs and investigating LSD1 inhibition in TP53-mutant murine models
Raajit Rampal • 24 Aug 2024
Novel agents under investigation in MPNs: MDM2, XPO1, and BET inhibitors 0:34
Novel agents under investigation in MPNs: MDM2, XPO1, and BET inhibitors
Raajit Rampal • 14 Jun 2024

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals